Sarepta Therapeutics Inc (NASDAQ:SRPT) stock rocketed after the drug company posted fourth quarter financial results that topped Wall Street estimates and Morgan Stanley (NYSE:MS) said the stock could rally nearly 50%.
For the period ended December 31, 2022, the Massachusetts-based company reported an adjusted earnings per share loss of $0.53, which beat analyst estimates for a loss of $0.83 per share. It also narrowed its loss from $0.77 per share in 4Q 2021.
During the quarter, Sarepta posted revenue of $258.43 million, which bested Wall Street expectations of $251.53 million.
READ: Harbor Custom Development continues Texas expansion in Horseshoe Bay with Wurzel Builders
The stock climbed nearly 20% to $146.15 in morning trade on the Nasdaq.
“Sarepta’s ability to launch Duchenne therapies and effectively serve the Duchenne patient community was once again on display in 2022 as we delivered nearly $236 million and $844 million in net product revenue for the quarter and year, respectively, and grew at 32% for the quarter and 38% for the year,” Sarepta CEO Doug Ingram said in a statement.
Duchenne muscular dystrophy is a rare genetic neuromuscular disease.
Meanwhile, Morgan Stanley (NYSE:MS) upgraded Sarepta from “equal weight” to an “overweight” rating. The upgrade came with a price target increase from $141 to $187 per share.
Contact the author Uttara Choudhury at uttara@proactiveinvestors.com
Follow her on Twitter: @UttaraProactive